Terrestrosin K is primarily studied for its anticoagulant properties, particularly its ability to inhibit platelet aggregation. This makes it a subject of interest in the development of therapies for cardiovascular diseases, where abnormal blood clotting plays a key role. It has shown potential in reducing the risk of thrombosis by interfering with platelet activation pathways, possibly through modulation of signaling molecules involved in clot formation. Due to its natural origin and specific mechanism, it is being explored as a lead compound for new antiplatelet drugs with fewer side effects compared to current treatments. Research is ongoing to evaluate its efficacy, safety, and possible applications in preventing stroke, heart attack, and other circulatory disorders.